Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action

被引:11
作者
Chang, Wei-Ting [1 ,2 ,3 ]
Lo, Yi-Ching [4 ]
Gao, Zi-Han [5 ]
Wu, Sheng-Nan [5 ,6 ,7 ]
机构
[1] Chi Mei Med Ctr, Div Cardiovasc Med, Tainan 71004, Taiwan
[2] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan 71004, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Dept Pharmacol, Kaohsiung 80708, Taiwan
[5] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan
[6] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan
[7] China Med Univ Hosp, Dept Basic Med Sci, Taichung 40402, Taiwan
关键词
roxadustat; delayed-rectifier K+ current; voltage-gated Na+ current; current kinetics; pituitary cell and heart cell; SENSITIVE POTASSIUM CHANNELS; RECTIFIER K+ CURRENT; IN-VITRO; HYPOXIA; EXPRESSION; HIF-1-ALPHA; ANEMIA; BLOCK; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; ANGIOGENESIS;
D O I
10.3390/ijms20236027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Roxadustat (FG-4592), an analog of 2-oxoglutarate, is an orally-administered, heterocyclic small molecule known to be an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase. However, none of the studies have thus far thoroughly investigated its possible perturbations on membrane ion currents in endocrine or heart cells. In our studies, the whole-cell current recordings of the patch-clamp technique showed that the presence of roxadustat effectively and differentially suppressed the peak and late components of I-K(DR) amplitude in response to membrane depolarization in pituitary tumor (GH(3)) cells with an IC50 value of 5.71 and 1.32 mu M, respectively. The current inactivation of I-K(DR) elicited by 10-sec membrane depolarization became raised in the presence of roxadustatt. When cells were exposed to either CoCl2 or deferoxamine (DFO), the I-K(DR) elicited by membrane depolarization was not modified; however, nonactin, a K+-selective ionophore, in continued presence of roxadustat, attenuated roxadustat-mediated inhibition of the amplitude. The steady-state inactivation of I-K(DR) could be constructed in the presence of roxadustat. Recovery of I-K(DR) block by roxadustat (3 and 10 mu M) could be fitted by a single exponential with 382 and 523 msec, respectively. The roxadustat addition slightly suppressed erg-mediated K+ or hyperpolarization-activated cation currents. This drug also decreased the peak amplitude of voltage-gated Na+ current with a slowing in inactivation rate of the current. Likewise, in H9c2 heart-derived cells, the addition of roxadustat suppressed I-K(DR) amplitude in combination with the shortening in inactivation time course of the current. In high glucose-treated H9c2 cells, roxadustat-mediated inhibition of I-K(DR) remained unchanged. Collectively, despite its suppression of HIF prolyl hydroxylase, inhibitory actions of roxadustat on different types of ionic currents possibly in a non-genomic fashion might provide another yet unidentified mechanism through which cellular functions are seriously perturbed, if similar findings occur in vivo.
引用
收藏
页数:21
相关论文
共 59 条
  • [1] Bruegge K, 2007, CURR MED CHEM, V14, P1853
  • [2] Activation of voltage-gated sodium current and inhibition of erg-mediated potassium current caused by telmisartan, an antagonist of angiotensin II type-1 receptor, in HL-1 atrial cardiomyocytes
    Chang, Wei-Ting
    Wu, Sheng-Nan
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2018, 45 (08) : 797 - 807
  • [3] Effects of Shenfu injection on chemotherapy-induced adverse effects and quality of life in patients with advanced nonsmall cell lung cancer: A systematic review and meta-analysis
    Chen, Gang
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S549 - S555
  • [4] Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
    Chen, N.
    Hao, C.
    Peng, X.
    Lin, H.
    Yin, A.
    Hao, L.
    Tao, Y.
    Liang, X.
    Liu, Z.
    Xing, C.
    Chen, J.
    Luo, L.
    Zuo, L.
    Liao, Y.
    Liu, B-C
    Leong, R.
    Wang, C.
    Liu, C.
    Neff, T.
    Szczech, L.
    Yu, K-H P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (11) : 1001 - 1010
  • [5] Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
    Chen, N.
    Hao, C.
    Liu, B-C
    Lin, H.
    Wang, Caili
    Xing, C.
    Liang, X.
    Jiang, G.
    Liu, Zhengrong
    Li, X.
    Zuo, L.
    Luo, L.
    Wang, J.
    Zhao, M.
    Liu, Zhihong
    Cai, G-Y
    Hao, L.
    Leong, R.
    Wang, Chunrong
    Liu, C.
    Neff, T.
    Szczech, L.
    Yu, K-H P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (11) : 1011 - 1022
  • [6] Evidence of Decreased Activity in Intermediate-Conductance Calcium-Activated Potassium Channels During Retinoic Acid-Induced Differentiation in Motor Neuron-Like NSC-34 Cells
    Chen, Pei-Chun
    Ruan, Jing-Syuna
    Wu, Sheng-Nan
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (06) : 2374 - 2388
  • [7] Roxadustat in the treatment of anaemia in chronic kidney disease
    Del Vecchio, Lucia
    Locatelli, Francesco
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 125 - 133
  • [8] Roxadustat: First Global Approval
    Dhillon, Sohita
    [J]. DRUGS, 2019, 79 (05) : 563 - 572
  • [9] Selective Blockade of HCN1/HCN2 Channels as a Potential Pharmacological Strategy Against Pain
    Dini, Leonardo
    Del Lungo, Martina
    Resta, Francesco
    Melchiorre, Michele
    Spinelli, Valentina
    Mannelli, Lorenzo Di Cesare
    Ghelardini, Carla
    Laurino, Annunziatina
    Sartiani, Laura
    Coppini, Raffaele
    Mannaioni, Guido
    Cerbai, Elisabetta
    Romanelli, Maria Novella
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [10] Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors
    Downie, Bryan R.
    Sanchez, Araceli
    Knoetgen, Hendrik
    Contreras-Jurado, Constanza
    Gymnopoulos, Marco
    Weber, Claudia
    Stuehmer, Walter
    Pardo, Luis A.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (52) : 36234 - 36240